The Senate Finance Committee today held a hearing on the Centers for Medicare & Medicaid Services’ proposed payment demonstration for Medicare Part B drugs. Patrick Conway, M.D., CMS acting principal deputy administrator, said the agency is reviewing comments on the proposed rule “to determine whether adjustments are needed. Our goal is to be responsive to the public comments and input from Congress while preserving the integrity and effectiveness of the model.” Committee Republicans have urged CMS to withdraw the proposal, while Democrats have said the model could reduce access to care and medications. In comments submitted last month, AHA said the model should not include hospitals, which have little control over which drugs physicians prescribe in hospital-based settings.

Related News Articles

Headline
Baxter Healthcare Corp., in coordination with the Food and Drug Administration, has agreed to temporarily import certain intravenous drug products, such…
Headline
President Trump yesterday named Eric Hargan as Acting Secretary of Health and Human Services. Confirmed as HHS deputy secretary last week, Hargan previously…
Headline
Hospitals generally support the proposed cancellation of the cardiac and Surgical Hip and Femur Fracture Treatment bundling program and Comprehensive Care for…
Headline
Twenty-three organizations, including the AHA, Friday urged the Centers for Medicare & Medicaid Services to suspend implementation of new draft Medicare…
Headline
More than 880,000 physicians were certified by the American Board of Medical Specialties in 2017, about 20,000 more than in 2016, according to the board’…
Headline
The Centers for Medicare & Medicaid Services has identified the first clinicians eligible to participate in 2018 advanced alternative payment models, based…